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OBJECTIVES: The relationship between adenosine deaminase and various cancers has been investigated in several
studies. However, serum adenosine deaminase activity and carbonic anhydrase and catalase activities in patients
with bladder cancer have not previously been reported. Therefore, the aim of this study was to measure serum
adenosine deaminase, carbonic anhydrase and catalase activities in patients with bladder cancer.
MATERIALS AND METHODS: Forty patients with bladder cancer and 30 healthy controls were enrolled in the study.
Serum adenosine deaminase, carbonic anhydrase and catalase activities were measured spectrophotometrically.
RESULTS: Serum adenosine deaminase, carbonic anhydrase and catalase activities were significantly higher in
patients with bladder cancer than controls (all significant, p,0.001).
CONCLUSIONS: These markers might be a potentially important finding as an additional diagnostic biochemical tool
for bladder cancer.
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INTRODUCTION
Bladder cancer is a common tumor of the urinary tract. It
is the fourth most common type of cancer in men in the
United States. The most common risk factors for bladder
cancer are exposure to industrial carcinogens, cigarette
smoking, male gender and, possibly, diet (1). The most
common type of bladder cancer develops from the
urothelium and is known as transitional cell carcinoma (2).
Some defense mechanisms in the body prevent the
development of free radicals and the damage they cause.
One of the most important antioxidant enzymes is superoxide
dismutase (SOD), which catalyzes the dismutation of super-
oxide anion into hydrogen peroxide (H2O2), which is removed
by catalase (CAT) and glutathione peroxidase (GSH-PX). CAT
is a well-known plasma antioxidant enzyme (3).
Carbonic anhydrase (CA) is a member of the alpha-family
of carbonic anhydrases of zinc metalloenzymes that catalyze
the reversible hydration of carbon dioxide to carbonic acid.
CAs have recently become a target of intensive research into
carcinogenesis and tumor invasion (4). The relationship
between CA and bladder cancer has been investigated in
several studies (5-8).
In the purine metabolic pathway, adenosine deaminase
(AD) is an important aminohydrolase. AD catalyzes the
conversion reaction of adenosine to inosine and deoxyade-
nosine to deoxyinosine (9). Its main physiologic activity is
related to lymphocytic proliferation and differentiation (10).
The relationship between adenosine deaminase and various
cancers has been investigated in several clinical studies, but
the results are conflicting. Although enzyme activity was
found to be increased in some cancerous tissue (11-13) in
several studies, it was typically decreased in various
neoplastic tissues (14,15). In addition, Watanabe et al.
showed the activity of curcumin in an animal bladder
cancer model, which most likely acted via the regulation of
nuclear factor-kappa B and p53. Curcumin decreased tumor
cell proliferation. Therefore, curcumin is a good choice for
treating superficial bladder cancer in clinical trials (16).
To the best of our knowledge, serum AD, CA, and CAT
activities in patients with bladder cancer have not previously
been reported. Therefore, the aim of this study was to
simultaneously investigate serum AD, CA, and CAT activ-
ities in patients with bladder cancer.
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This prospective cross-sectional study included 40 male
patients who were newly diagnosed (preoperative) with
bladder cancer (mean age of 65.32¡3.4 years) between
January 2011 and October 2011 and treated at the Department
of Urology at the University Hospital of Yuzuncu Yil.
All patients were lifetime non-smokers and free of drug,
alcohol, or antioxidant supplement consumption and any
metabolic disease. None of the patients had any other
significant disease or malignancies except for bladder cancer,
and only newly diagnosed patients (preoperative) with no
prior chemotherapeutic treatment were included in this
study.
Controls consisted of 30 healthy males (mean age of
60.82¡5.2 years) randomly selected from a group of healthy
non-smoking volunteers with no history of previous disease
or drug or alcohol consumption.
The patient and control groups were of similar socio-
economic status. Regarding tumor staging, 30 patients were
diagnosed with a non-invasive tumor (Ta–T1), and 10
patients were diagnosed with an invasive tumor (T2–T4).
Patients were classified into three groups with respect to
tumor grading: 24 patients had well-differentiated tumors
(G1), 10 had intermediate tumors (G2), and six had poorly
differentiated (G3) tumors. The superficial urothelial papil-
lary tumors were graded according to the 2004 World
Health Organization (WHO) grading system as low-grade
and high-grade papillary neoplasms.
The study protocol was performed in accordance with the
Helsinki Declaration as revised in 1989. All participants
were informed about the study protocol, and written
consent was obtained from each participant.
Blood collection
Blood samples were obtained in the morning after 12 h of
fasting. Blood samples were collected into empty tubes and
immediately stored on ice at 4 C˚. The serum was then
separated from the cells by centrifugation at 3,000 rpm for
10 min. Serum samples used for the measurement of AD, CA,
and CAT levels were stored at -20 C˚ until they were used.
Measurement of adenosine deaminase activity
Serum AD activity was estimated spectrophotometrically
by the method of Giusti, which is based on the direct
measurement ammonia formation, which occurs when AD
is in the presence of excess adenosine (17). The results were
expressed as units per liter (U/L).
Measurement of carbonic anhydrase enzyme
activity
Serum CA activity was assayed by CO2 hydration. The
hydration of CO2 was measured using the method of Rickli
and Wilbur-Anderson, with bromothymol blue as the
indicator (18). The results were expressed as units per liter
(U/L).
Measurement of catalase activity
Serum CAT activity was measured using H2O2 as a substrate
(19). The degradation of H2O2 was monitored at 240 nm for
5 min using a spectrophotometer, and enzyme activity was
expressed in units per liter of serum (U/L) at 25 C˚.
Statistical analysis
The results are expressed as the mean¡standard devia-
tion. Continuous variables were compared using Student’s t
test. Nonparametric continuous variables were compared
using a Kruskal–Wallis one-way analysis of variance with a
Mann–Whitney U-test post-hoc analysis. The results were
considered to be statistically significant when the p-value
was less than 0.05. The data were analyzed using the SPSSH
for Windows computing program (version 11.0).
RESULTS
The demographic and clinical data of the bladder cancer
and control groups are shown in Table 1. There were no
statistically significant differences between bladder cancer
patients and controls with respect to age and body mass
index (p.0.05) (Table 1).
AD, CA, and CAT activities were detected in all samples.
The mean activities of the enzymes are summarized in
Table 2.
In the healthy controls, the serum AD, CA, and CAT
mean values of activities were 16.4¡0.4, 0.65¡0.19, and
1.15¡0.04 U/L, respectively (Table 2).
In patients with bladder cancer, the serum AD, CA, and
CAT mean values of activities were 26.1¡2.1, 0.96¡0.20,
and 1.85¡0.07 U/L, respectively (Table 2).
The serum AD, CA, and CAT mean values of activities
were significantly higher in patients with bladder cancer
than in healthy controls (all significant; p,0.001) (Table 2).
DISCUSSION
In this study, we analyzed serum CA and CAT levels in
patients with bladder cancer. In addition, we studied the
activity of serum AD, which is an important aminohydro-
lase in purine metabolism, in patients with bladder cancer.
Additionally, we aimed to determine the relationship
between these enzyme activities in patients with bladder
cancer.
We observed that serum AD, CA, and CAT levels were
significantly higher in patients with bladder cancer than in
healthy controls. To the best of our knowledge, no other
studies have examined serum AD, CA, and CAT levels in
Table 1 - Demographic characteristics of the two groups
in this study.
Parameters Control (n = 30) Patients (n = 40) p-value
Age (years) 60.82¡5.2 65.32¡3.4 ns
Body mass index (kg/m2) 22.56¡2.43 23.12¡1.62 ns
Values are the mean¡SD;
ns =non-significant.
Table 2 - Serum adenosine deaminase, carbonic
anhydrase and catalase activities in the two groups in this
study.
Parameters Control (n = 30) Patients (n = 40) p-value
Adenosine deaminase (U/L) 16.4¡0.4 26.1¡2.1 ,0.001
Carbonic anhydrase (U/L) 0.65¡0.19 0.96¡0.20 ,0.001
Catalase (U/L) 1.15¡0.04 1.85¡0.07 ,0.001
Values are the mean¡SD.
Significant, p,0.001.
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patients with bladder cancer. Increased serum AD, CA, and
CAT activities may play a role in the pathogenesis of
bladder cancer. Therefore, we believe that serum AD, CA,
and CAT levels may be an informative prognostic marker
for bladder cancer. The activities of AD, CAT, and CA in
patients with bladder tumors can also be measured in the
urine. The follow-up to determine recurrence, particularly
after the treatment of bladder tumors, may benefit from
determining the activities of this enzyme before cystoscopy.
AD, which catalyzes the reaction in which adenosine is
deaminated to inosine, has been accepted as an important
enzyme in the maturation, proliferation, differentiation, and
function of T lymphocytes (20). As an indicator of cellular
immunity, the plasma activity of this enzyme has been
suggested to be increased in diseases that cause a cell-
mediated immune response, such as cancer (21).
Some studies have confirmed the value of estimating AD
in the diagnosis and follow-up of patients with tuberculosis
(22). Recent studies have focused on the diagnostic value of
AD activity in typical (10,23) and atypical (24) pneumonia.
AD activity was increased in cancerous tissues and cells
compared to noncancerous tissue in several studies (11-13).
Some authors, however, found low lymphocyte AD activ-
ities in cancer patients (14,15). Sufrin et al. (13) found that
the AD levels in lymphocytes from patients with bladder
cancer were elevated with transitional cell carcinoma and
correlated with stage, activity, clinical course, and tumor
resection but not tumor grade. These researchers also found
higher erythrocyte AD activities in the same patients and
suggested that lymphocyte AD levels might be a sensitive
indicator of bladder carcinoma. The high AD activity
determined in cancerous bladder tissue reflected accelerated
purine turnover and high salvage pathway activity (12).
Similarly, Durak et al. (13) found increased AD activity in
cancerous bladder tissues compared with adjacent cancer-
free tissues and control bladder tissues. Our results are in
agreement with those studies (12,13).
In contrast, Lal et al. (25) demonstrated that the increase in
serum AD activity was directly related to the cancer stage,
indicating that the increase was directly proportional to the
primary tumor mass. Moreover, Nishihara et al. (26) reported
that patients with lung cancer had elevated AD levels and
that serum AD levels were significantly reduced in patients
with lung cancer following surgery and radiotherapy. In
contrast, Dasmahapatra et al. (14) and Kojima et al. (15) found
low lymphocyte AD activities in head and neck cancer
patients and gastric cancer patients, respectively. They
suggested that low lymphocyte AD activities might be a
more sensitive indicator of suppressed cellular immunity.
In the present study, we observed that serum AD activity
was significantly higher in patients with bladder cancer
than in healthy controls. Increased AD activity might
provide a selective advantage for cancer cells to grow and
develop more rapidly. We speculate that increased AD
activity might be a result of the leakage of the enzyme from
primary tumor cells.
CAT is highly expressed in some tissues and protects cells
against the excessive formation of reactive oxygen species.
CAT prevents the accumulation of H2O2 formed during
oxygen transport. Although there is accumulating evidence
that CAT activity is suppressed in cancerous tissues (13,27-
29), some authors found unchanged or increased activity in
some tumor tissues (30,31). Durak et al. (13) found
decreased CAT activity in cancerous bladder tissues
compared with adjacent cancer-free tissues and control
bladder tissues. In contrast, Bayraktar et al. (31) recently
reported that patients with bladder cancer had increased
CAT levels. Several studies have shown decreased CAT
levels in patients with lung cancer (27,28). Moreover,
Corrocher et al. (29) reported decreased CAT activity in
human hepatoma and suggested that the antioxidant
defense system of hepatocellular carcinoma cells was
severely impaired. In contrast, Bayraktar et al. (31) recently
reported that patients with bladder cancer had increased
CAT levels. The higher CAT activity observed in this study
supports previous observations that the enzymatic antiox-
idant defense mechanism is not impaired in tumor cells and
tissue, although this was not a universal characteristic of
neoplastic cells.
In the present study, we found significantly increased
CAT activity in the serum of bladder cancer patients. Our
data clearly demonstrate that CAT activity is increased in
patients with bladder cancer, and thus, our results are not in
agreement with Durak et al. (13). However, our results are
in agreement with Bayraktar et al. (31).
CAs are involved in several physiological and biological
processes in humans. CA is not only a highly active enzyme
but is also involved in cell-cell adhesion and cell prolifera-
tion (32), and it plays different roles in various tissues.
Species can produce many different CA isozymes, some of
which act in the cytosol, while others are membrane bound.
For example, in humans, there are three cytosolic isozymes
(CA-I, II, and III), five membrane-bound isozymes, and
several related proteins that lack catalytic activity. CA-I is
found primarily in erythrocytes. The human CA-II isozyme
is widely distributed, and it has been identified in
erythrocytes and the brain, eyes, and kidneys (4). Carbonic
anhydrase IX (CAIX) is a hypoxia-inducible member of the
carbonic anhydrase family that regulates intracellular pH,
cell proliferation, cell adhesion, and tumor progression.
Studies have demonstrated that high CAIX expression
yields an aggressive tumor phenotype and a poor prognosis
in many cancer types. However, with regard to bladder
cancer, there have been only a few reports on a limited
number of patients, and those reports produced inconclu-
sive results (5,7,8). CAs are key enzymes that regulate acid-
base homeostasis under both normal and pathological
conditions (33). CA is abundantly expressed as a direct
consequence of hypoxia in numerous cancers (34), and its
activity has been documented in some cancerous tissues
(5,7,8). However, there is limited information regarding
serum CA activity in patients with bladder cancer (6). In the
present study, we found significantly increased CA activity
in the serum of bladder cancer patients.
The current study is the first to investigate serum AD, CA,
and CAT activities in patients with bladder cancer. These
markers might be potentially important as an additional
biochemical diagnostic tool for bladder cancer. Further
investigations in a larger cohort of patients with bladder
cancer are needed to provide definitive data about the
prognostic role of AD, CA, and CAT activities.
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